Class / Patent application number | Description | Number of patent applications / Date published |
514288000 | Ring carbon is shared by three of the cyclos | 23 |
20090264456 | COMPOSTIONS AND METHODS FOR PREVENTING AND/OR TREATING DISORDERS ASOCIATED WITH CEPHALIC PAIN - Compounds, e.g., of formula (I) and (Ia), pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions for treating pain disorders, e.g., disorders associated with cephalic pain, are provided. | 10-22-2009 |
20100113499 | MEDICAMENT FOR THE TREATMENT OF ENDOMETRIOSIS - The use of a dopamine agonist in the manufacture of a medicament for the treatment or prevention of endometriosis. | 05-06-2010 |
20100137351 | Imidazoacridinone derivative compounds and methods for their use - The present invention provides IA derivative compounds of the formula: | 06-03-2010 |
20100152223 | CRYSTAL FORM OF CABERGOLINE - The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form. | 06-17-2010 |
20130158064 | NOVEL ISO-ERGOLINE DERIVATIVES - Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 06-20-2013 |
20130165469 | NOVEL NEUROMODULATORY COMPOUNDS - Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 06-27-2013 |
20130190345 | MATRINIC ACID/MATRINE DERIVATIVES AND PREPARATION METHODS AND USES THEREOF - The present invention relates to a N-substituted matrinic acid derivative or matrine derivative, and its preparation method and uses. Specifically, the present invention relates to a compound of Formula (I) or (II) (wherein all the definitions of substituted groups are those mentioned in the specification), or a pharmaceutically acceptable salt, geometric isomer, stereoisomer, solvate, ester or prodrug thereof. The present invention further relates to a method for preparing the compound of the present invention, a pharmaceutical composition containing the compound, and uses thereof in manufacture of a medicament. The compound of the present invention can be used for prophylaxis and/or treatment of a disease or disorder associated with viral infection such as hepatitis B and/orhepatitis C and/or AIDS. | 07-25-2013 |
20130197023 | NEUROPROTECTION BY PHARMACOLOGICAL CHAPERONING OF NICOTINIC ACETYLCHOLINE RECEPTORS - A method of ameliorating an endoplasmic reticulum (ER) stress response and/or unfolded protein response (UPR) in cells expressing nicotinic acetylcholine receptors (nAChRs) comprises contacting a cell expressing nAChRs with an effective amount of a ligand for nAChRs. The contacting results in attenuating endogenously expressed ATF6 translocation, expression of XBP1, phosphorylation of eukaryotic initiation factor 2α (peIF2α), increased numbers of ER exit sites, increased trafficking of known associated proteins as well as other proteins such as growth factors and their receptors, changes in abundance of selected mRNA species, and phosphorylation, abundance, or subcellular compartmentalization of other proteins involved with ER stress and/or the UPR, and inhibiting upregulation of CCAAT/Enhancer-Binding Protein Homologous Protein (CHOP) levels in the cells. The method can be used to screen for neuropharmacotherapeutic agents and to treat or prevent neurodegenerative disease, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, or cognitive deficiency. | 08-01-2013 |
20130203798 | DIAGNOSIS AND TREATMENT OF FUNCTIONAL DYSPEPSIA AND IRRITABLE BOWEL SYNDROME - Methods for diagnosing, monitoring, and treating functional dyspepsia and/or irritable bowel syndrome, are disclosed comprising determining the presence of enterovirus in a gastrointestinal biopsy, wherein the presence of enterovirus indicates disease. | 08-08-2013 |
20130252996 | METHODS AND KITS FOR TREATING CLUSTER HEADACHE DISORDERS - The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders. | 09-26-2013 |
20130345253 | NOVEL CABERGOLINE DERIVATIVES - Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT | 12-26-2013 |
20140024670 | VETERINARY ANTI-PROLACTIN COMPOSITION FOR RUMINANTS - The present invention relates to a veterinary anti-prolactin composition to be administered to ruminants. Said composition includes at least one anti-prolactin compound which is an agonist for dopamine receptors and which is particularly useful for preventing and/or reducing the harmful effects in ruminants linked to use for a shortened dry period. Said composition is particularly useful for preventing and/or reducing metabolic diseases and/or reproductive disorders when lactation is resumed. The use of the veterinary anti-prolactin composition according to the invention does not adversely affect the milk-producing ability and/or the milk quality of the treated ruminants | 01-23-2014 |
20140045879 | Pharmaceutical Compositions for the Treatment of Capillary Arteriopathy - The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome. | 02-13-2014 |
20140051717 | METHODS AND SYSTEMS FOR TREATMENT OF MIGRAINES AND OTHER INDICATIONS - The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ergopeptines, triptans, and other compounds, including salts and derivatives of these, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 02-20-2014 |
20140094483 | NOVEL ISO-ERGOLINE DERIVATIVES - Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 04-03-2014 |
20140113927 | TREATMENT UTILIZING HYDROPHOBIC WEAK BASES CHEMOTHERAPEUTIC AGENTS AND ILLUMINATION - Hydrophobic weak base compounds such as hydrophobic weak base chemotherapeutic agents (which are not an anthracycline) for use in the treatment of medical conditions such as proliferative disease or disorder in a subject, in combination with illumination of a region in a body of the subject which is characterized by the presence of proliferating cells, are disclosed. The hydrophobic weak base compound and a wavelength of illumination are selected such that the hydrophobic weak base compound acts as a therapeutically effective photosensitizer when exposed to the illumination. | 04-24-2014 |
20140179730 | NOVEL METHYSERGIDE DERIVATIVES - Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT | 06-26-2014 |
20150031719 | Topical Therapy for the Treatment of Migraines, Muscle Sprains, Muscle Spasms, Spasticity and Related Conditions - The invention is directed to topical formulations and methods of treating a migraines and/or cluster headaches, muscle sprains, muscle spasms, spasticity, tension headaches, tension related migraines and related conditions associated with muscle tension and pain with a therapeutically effective amount of an ergot alkaloid, skeletal muscle relaxant, serotonin agonist, combinations thereof, pharmaceutically acceptable salt thereof, prodrugs thereof or derivative thereof. | 01-29-2015 |
20150038525 | NOVEL METHYSERGIDE DERIVATIVES - Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migraine and Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein, such as, for example, are methods for antagonizing the 5-HT | 02-05-2015 |
20150148371 | NOVEL NEUROMODULATORY COMPOUNDS - Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 05-28-2015 |
20160015696 | MICROBICIDAL COMPOSITION COMPRISING AN OCTOXYNOL AND A QUINOLIZIDINE ALKALOID COMPOUND OR A SOURCE THEREOF - The present invention provides microbicidal compositions comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof, and methods of using the compositions. The quinolizidine alkaloid compound has a structure: | 01-21-2016 |
20160175292 | Antioxidants Having Aromatic Structures Reacting with Superoxide | 06-23-2016 |
20160199367 | Composition for the prevention or treatment of the symptoms in the stroke comprising the inhibitor of Pin1 | 07-14-2016 |